Johnson & Johnson recently held their second-quarter 2025 earnings conference call, providing insights into the company's performance and future outlook. Key attendees included Darren Snellgrove, Vice President of Investor Relations, Joaquin Duato, Chairman of the Board, Chief Executive Officer, and Joseph Wolk, Chief Financial Officer. During the call, management highlighted the strength of their diversified business and projected elevated growth in the latter half of the year. Significant milestones are anticipated in areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular. These advancements are expected to "extend and improve lives in transformative ways and deliver significant value to patients and shareholders," as noted by a member of the management team. The full transcript can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.